CLINICAL TRIALS PROFILE FOR RANITIDINE BISMUTH CITRATE
✉ Email this page to a colleague
All Clinical Trials for ranitidine bismuth citrate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00985608 ↗ | Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study | Unknown status | Catholic University of the Sacred Heart | Phase 2 | 2009-04-01 | H pylori gastric infection is one of the most prevalent infectious diseases worldwide. The discovery that most upper gastrointestinal diseases are related to H pylori infection and therefore can be treated with antibiotics is an important medical advance. Currently, a first-line triple therapy based on proton pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) plus two antibiotics (clarithromycin and amoxicillin or nitroimidazole) is recommended by all consensus conferences and guidelines. Even with the correct use of this drug combination, infection can not be eradicated in up to 23% of patients. Therefore, several second line therapies have been recommended. A 7 d quadruple therapy based on PPI, bismuth, tetracycline and metronidazole is the more frequently accepted. However, with second-line therapy, bacterial eradication may fail in up to 40% of cases. When H pylori eradication is strictly indicated the choice of further treatment is controversial. When available, endoscopy with culture and consequent antibiotic susceptibility testing remains the most appropriate option for patients with two eradication failures to avoid a widespread use of expensive antibiotics. The use of these drugs may also induce severe side-effects and development of H pylori resistant strains. Resistant strains of Helicobacter pylori can display a dense biofilm with mucus and microorganisms in a coccoid shape on the mucosal surface of stomach that may have a role in determining the resistance to the antibiotic therapies. Possibly, N-acetil-cysteine (NAC) may dissolve biofilm architecture and help to eradicate resistant strains of H pylori. |
NCT02017197 ↗ | Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 | 2014-08-01 | The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks. |
NCT02017197 ↗ | Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil | Completed | Federal University of São Paulo | Phase 4 | 2014-08-01 | The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ranitidine bismuth citrate
Condition Name
Clinical Trial Locations for ranitidine bismuth citrate
Clinical Trial Progress for ranitidine bismuth citrate
Clinical Trial Phase
Clinical Trial Sponsors for ranitidine bismuth citrate
Sponsor Name